Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy

References

• Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.
   PubMed Web of Science ®Google Scholar
• Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007;19:124–134.
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303.
   PubMed Web of Science ®Google Scholar
• Prickett TD, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet. 2009;41:1127–1132.
   PubMed Web of Science ®Google Scholar
• Mendoza‐Naranjo A, El‐Naggar A, Wai DH, et al. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med. 2013;5:1087–1102.
   PubMed Web of Science ®Google Scholar
• Lin NU, Winer EP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004;6:1.
   PubMed Web of Science ®Google Scholar
• Kainulainen V, Sundvall M, Määttä JA, et al. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem. 2000;275:8641–8649.
   PubMed Web of Science ®Google Scholar
• Qiu C, Tarrant MK, Choi SH, et al. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure. 2008;16:460–467.
   PubMed Web of Science ®Google Scholar
• Naresh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006;66:6412–6420.
   PubMed Web of Science ®Google Scholar
• Vidal G, Clark D, Marrero L, et al. A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities. Oncogene. 2007;26:462–466.
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–354.
   PubMed Web of Science ®Google Scholar
• Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003;284:99–110.
   PubMed Web of Science ®Google Scholar
• Jackson-Fisher A, Bellinger G, Shum E, et al. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene. 2006;25:5664–5672.
   PubMed Web of Science ®Google Scholar
• Canfield K, Li J, Wilkins OM, et al. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 2015;14:648–655.
   PubMed Web of Science ®Google Scholar
• Suo Z, Siri Berner H, Risberg B, et al. Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch. 2001;439:62–69.
   PubMed Web of Science ®Google Scholar
• Hollmén M, Liu P, Kurppa K, et al. Proteolytic processing of ErbB4 in breast cancer. PLoS One. 2012;7:e39413.
   PubMed Web of Science ®Google Scholar
• Sartor CI, Zhou H, Kozlowska E, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 2001;21:4265–4275.
   PubMed Web of Science ®Google Scholar
• Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290–297.
   PubMed Web of Science ®Google Scholar
• Lodge A, Anderson J, Gullick WJ, et al. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol. 2003;56:300.
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Gillett CE, Barnes DM, et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 2000;60:1483–1487.
   PubMed Web of Science ®Google Scholar
• Maatta JA, Sundvall M, Junttila TT, et al. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell. 2006;17:67–79. Epub 2005/10/28.
   PubMed Web of Science ®Google Scholar
• Kim J-Y, Jung HH, Do IG, et al. Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer. 2016;16:138.
   PubMed Web of Science ®Google Scholar
• Junttila TT, Sundvall M, Lundin M, et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res. 2005;65:1384–1393.
   PubMed Web of Science ®Google Scholar
• Tovey SM, Witton CJ, Bartlett JM, et al. Outcome and human epithelial growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling. Breast Cancer Res. 2004;6:R246.
   PubMed Web of Science ®Google Scholar
• Boratyn GM, Schäffer AA, Agarwala R, et al. Domain enhanced lookup time accelerated BLAST. Biol Direct. 2012;7:12.
   PubMed Web of Science ®Google Scholar
• Notredame C, Higgins DG, Heringa J. T-Coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol. 2000;302:205–217.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28:235–242.
   PubMed Web of Science ®Google Scholar
• DeLano WL. The PyMOL molecular graphics system. San Carlos, CA: DeLano Scientific; 2002. http://www.pymol.org
   Google Scholar
• Fiser A, Do RKG, Šali A. Modeling of loops in protein structures. Protein Sci. 2000;9:1753–1773.
   PubMed Web of Science ®Google Scholar
• Fiser A, Sali A. ModLoop: automated modeling of loops in protein structures. Bioinformatics. 2003;19:2500–2501.
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Cheng J. 3Drefine: consistent protein structure refinement by optimizing hydrogen bonding network and atomic‐level energy minimization. Proteins. 2013;81:119–131.
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Cheng J. i3Drefine software for protein 3D structure refinement and its assessment in CASP10. PLoS One. 2013;8:e69648.
   PubMed Web of Science ®Google Scholar
• Lovell SC, Davis IW, Arendall WB, 3rd, et al. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins. 2003;50:437–450. Epub 2003/01/31.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Sasisekharan V. Conformation of polypeptides and proteins. Adv Protein Chem. 1968;23:283–437.
   PubMedGoogle Scholar
• Laskowski RA, MacArthur MW, Moss DS, et al. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283–291.
   Web of Science ®Google Scholar
• Dundas J, Ouyang Z, Tseng J, et al. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006;34:W116–W1W8.
   PubMed Web of Science ®Google Scholar
• Volkamer A, Kuhn D, Rippmann F, et al. DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment. Bioinformatics. 2012;28:2074–2075.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:D668–D672. Epub 2005/12/31.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:D668–DD72.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–461.
   PubMed Web of Science ®Google Scholar
• Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3:935–949.
   PubMed Web of Science ®Google Scholar
• Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24:417–422.
   PubMed Web of Science ®Google Scholar
• Morris AL, MacArthur MW, Hutchinson EG, et al. Stereochemical quality of protein structure coordinates. Proteins. 1992;12:345–364.
   PubMed Web of Science ®Google Scholar
• Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44:235–249.
   PubMed Web of Science ®Google Scholar
• Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51:2778–2786.
   PubMed Web of Science ®Google Scholar
• Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng Des Sel. 1995;8:127–134.
   Web of Science ®Google Scholar
• Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol. 1999;294:1351–1362.
   PubMed Web of Science ®Google Scholar
• Ramachandran GN, Ramakrishnan C, Sasisekharan V. Stereochemistry of polypeptide chain configurations. J Mol Biol. 1963;7:95–99.
   PubMed Web of Science ®Google Scholar
• Binkowski TA, Naghibzadeh S, Liang J. CASTp: computed atlas of surface topography of proteins. Nucleic Acids Res. 2003;31:3352–3355.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64:4–17.
   Web of Science ®Google Scholar
• Verma A. Lead finding from Phyllanthus debelis with hepatoprotective potentials. Asian Pac J Trop Biomed. 2012;2:S1735–S17S7.
   Google Scholar
• Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127–132.
   PubMed Web of Science ®Google Scholar
• Huang Y, Rizzo RC. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases. Biochemistry. 2012;51:2390–2406.
   PubMed Web of Science ®Google Scholar
• Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1:85–94.
   PubMed Web of Science ®Google Scholar
• Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol. 2001;28(5 Suppl 16):80–85.
   Google Scholar
• Gschwantler-Kaulich D, Grunt TW, Muhr D, et al. HER specific TKIs exert their antineoplastic effects on breast cancer cell lines through the involvement of STAT5 and JNK. PLoS One. 2016;11:e0146311.
   PubMed Web of Science ®Google Scholar